AlTi Global Inc. Sells 4,458 Shares of Johnson & Johnson $JNJ

AlTi Global Inc. trimmed its position in Johnson & Johnson (NYSE:JNJ) by 4.7% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 89,816 shares of the company’s stock after selling 4,458 shares during the period. AlTi Global Inc.’s holdings in Johnson & Johnson were worth $16,653,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Prospera Financial Services Inc boosted its stake in shares of Johnson & Johnson by 1.4% in the 3rd quarter. Prospera Financial Services Inc now owns 90,412 shares of the company’s stock worth $16,778,000 after buying an additional 1,270 shares during the last quarter. Oppenheimer & Co. Inc. lifted its holdings in Johnson & Johnson by 0.7% during the third quarter. Oppenheimer & Co. Inc. now owns 183,351 shares of the company’s stock worth $33,997,000 after acquiring an additional 1,273 shares during the period. Western Wealth Management LLC boosted its position in Johnson & Johnson by 0.6% in the third quarter. Western Wealth Management LLC now owns 15,373 shares of the company’s stock worth $2,850,000 after purchasing an additional 91 shares during the last quarter. D.B. Root & Company LLC grew its stake in Johnson & Johnson by 6.2% in the 3rd quarter. D.B. Root & Company LLC now owns 3,236 shares of the company’s stock valued at $600,000 after purchasing an additional 190 shares during the period. Finally, REAP Financial Group LLC increased its position in shares of Johnson & Johnson by 8.1% during the 3rd quarter. REAP Financial Group LLC now owns 2,353 shares of the company’s stock valued at $436,000 after purchasing an additional 177 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.6%

Shares of NYSE:JNJ opened at $238.62 on Tuesday. The firm has a fifty day moving average price of $214.20 and a two-hundred day moving average price of $194.70. The company has a market cap of $574.90 billion, a price-to-earnings ratio of 21.59, a PEG ratio of 2.33 and a beta of 0.35. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a one year low of $141.50 and a one year high of $240.93.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company had revenue of $24.56 billion for the quarter, compared to the consensus estimate of $24.14 billion. During the same quarter last year, the business posted $2.04 earnings per share. The firm’s revenue was up 9.1% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research analyst reports. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Stifel Nicolaus lifted their price target on shares of Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. TD Cowen lifted their price objective on Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Barclays upped their price objective on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a report on Tuesday, December 30th. Finally, Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.